Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano Sells 923 Shares

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Friday, November 17th. The shares were sold at an average price of $177.46, for a total value of $163,795.58. Following the completion of the transaction, the executive vice president now owns 22,665 shares of the company’s stock, valued at approximately $4,022,130.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Roxanne Lagano also recently made the following trade(s):

• On Wednesday, October 18th, Roxanne Lagano sold 923 shares of Zoetis stock. The shares were sold at an average price of $172.92, for a total value of $159,605.16.
• On Monday, September 18th, Roxanne Lagano sold 923 shares of Zoetis stock. The shares were sold at an average price of $179.58, for a total transaction of $165,752.34.
• On Friday, September 1st, Roxanne Lagano sold 923 shares of Zoetis stock. The shares were sold at an average price of $192.97, for a total transaction of $178,111.31.

Zoetis Stock Up 0.7 %

Shares of Zoetis stock traded up $1.26 during trading on Monday, reaching $176.06. The stock had a trading volume of 1,056,233 shares, compared to its average volume of 1,973,395. The company has a market capitalization of $80.83 billion, a price-to-earnings ratio of 35.53, a P/E/G ratio of 2.85 and a beta of 0.83. The stock has a fifty day moving average price of $171.85 and a two-hundred day moving average price of $175.65. The company has a current ratio of 3.87, a quick ratio of 2.16 and a debt-to-equity ratio of 1.29. Zoetis Inc. has a 52 week low of $140.76 and a 52 week high of $194.99.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Wednesday, November 1st will be given a $0.375 dividend. The ex-dividend date of this dividend is Tuesday, October 31st. This represents a $1.50 dividend on an annualized basis and a dividend yield of 0.85%. Zoetis’s payout ratio is presently 30.49%.

Hedge Funds Weigh In On Zoetis

A number of hedge funds have recently bought and sold shares of ZTS. Evermay Wealth Management LLC raised its position in shares of Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after buying an additional 123 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after acquiring an additional 112 shares in the last quarter. Worth Asset Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth $26,000. Pacifica Partners Inc. increased its position in shares of Zoetis by 76.9% in the second quarter. Pacifica Partners Inc. now owns 161 shares of the company’s stock worth $27,000 after purchasing an additional 70 shares during the period. Finally, Altshuler Shaham Ltd acquired a new position in Zoetis in the second quarter valued at about $29,000. 89.47% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ZTS. HSBC assumed coverage on shares of Zoetis in a research report on Wednesday, September 6th. They set a “buy” rating and a $230.00 target price on the stock. Argus raised their price objective on shares of Zoetis from $190.00 to $201.00 in a research note on Tuesday, September 19th. The Goldman Sachs Group upped their target price on shares of Zoetis from $204.00 to $213.00 and gave the company a “buy” rating in a research report on Wednesday, August 9th. Stifel Nicolaus reduced their target price on Zoetis from $205.00 to $195.00 and set a “buy” rating on the stock in a report on Monday, October 30th. Finally, StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 8th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average target price of $216.29.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.